A T-cell engaging bispecific antibody with a tumor-selective bivalent folate receptor alpha binding arm for the treatment of ovarian cancer.
Avanzino BC, Prabhakar K, Dalvi P, Hartstein S, Kehm H, Balasubramani A, Boudreau AA, Buelow B, Chang K, Davison LM, Iyer S, Kalwit V, Lewis Wilson K, Malik-Chaudhry HK, Pierson W, Pineda G, Rangaswamy US, Saiganesh S, Schellenberger U, Ugamraj HS, Yabut RD, Buelow R, Chapman J, Trinklein ND, Harris KE.
Avanzino BC, et al. Among authors: prabhakar k.
Oncoimmunology. 2022 Aug 20;11(1):2113697. doi: 10.1080/2162402X.2022.2113697. eCollection 2022.
Oncoimmunology. 2022.
PMID: 36016696
Free PMC article.